Intangible Assets - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Finite Lived Intangible Assets [Line Items]
Amortization expense	$ 425,107	$ 425,107	$ 1,275,322	$ 1,289,206
Amortization of license agreements remainder of fiscal year 2017	425,107		425,107
Amortization of license agreements in 2018	1,700,429		1,700,429
Amortization of license agreements in 2019	1,700,429		1,700,429
Amortization of license agreements in 2020	1,700,429		1,700,429
Amortization of license agreements in 2021	1,700,429		1,700,429
Amortization of license agreements in 2022	1,700,429		1,700,429
Amortization of license agreements, thereafter	11,962,294		$ 11,962,294
Novartis | Licensing Agreements
Finite Lived Intangible Assets [Line Items]
Amortization period of intangible assets			21 years
Finite-lived intangible assets, accumulated amortization	346,279		$ 346,279
Novartis | Patents
Finite Lived Intangible Assets [Line Items]
Amortization period of intangible assets			14 years
Finite-lived intangible assets, accumulated amortization	$ 3,621,389		$ 3,621,389